Loading...
•
Sep 30, 2024
Prestige Consumer Q2 2025 Earnings Report
Prestige Consumer's Q2 2025 financial results exceeded expectations, driven by strong international growth and disciplined capital deployment.
Key Takeaways
Prestige Consumer Healthcare reported Q2 2025 revenue of $283.8 million, a slight decrease of 0.9% year-over-year, but ahead of expectations. Diluted EPS increased by 2% to $1.09. The company reaffirmed its full-year fiscal 2025 revenue, earnings, and cash flow outlook.
Q2 revenue reached $283.8 million, surpassing the company's outlook.
Diluted EPS for Q2 was $1.09, a 2% increase compared to the previous year.
Net cash from operating activities for the first six months was approximately $125 million, up approximately 13%.
The company reduced debt by $75 million and repurchased $38 million in shares year-to-date.
Prestige Consumer
Prestige Consumer
Prestige Consumer Revenue by Segment
Revenue by Segment
North American OTC Healthcare Revenue
CapyFin.comInternational OTC Healthcare Revenue
CapyFin.com Forward Guidance
Prestige Consumer Healthcare reaffirmed its fiscal year 2025 outlook for sales, adjusted earnings, and cash flow, expecting adjusted EPS to be at the higher end of the outlook.
Positive Outlook
- Diverse portfolio of brands
- Second half revenue growth building on first half momentum in the international segment
- Continued improvements for the Women’s Health category
- Disciplined capital allocation
- Strong free cash flows enabling lower interest expense and shares outstanding
Challenges Ahead
- Continued supply constraints for Clear Eyes
- Declines in the Cough & Cold category
- Declines in the Analgesic categories
- Revenue performance versus the prior year comparable period reflected anticipated limited ability to supply strong demand for Clear Eyes
- Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.
Revenue & Expenses
Visualization of income flow from segment revenue to net income